title: Erythropoietin - Neonatal Intensive Care Drug Manual
text: References
  |
  1. Maier RF, Obladen M, Müller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. The Journal of pediatrics. 2002;141(1):8-15.
  2. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. New England Journal of Medicine. 1994;330(17):1173-8.
  3. Avent M, Cory B, Galpin J, Ballot D, Cooper P, Sherman G, et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of tropical pediatrics. 2002;48(4):227-33.
  4. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. The Journal of pediatrics. 1992;121(1):98-102.
  5. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood-Fetal and Neonatal Edition. 1998;79(1):F44-F8.
  6. Ohlsson A, Aher SM. Early erythropoiesis‐stimulating agents in preterm or low birth weight infants. Cochrane Database of Systematic Reviews. 2020(2).
  7. Aher SM, Ohlsson A. Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database of Systematic Reviews. 2020(1).
  |